You asked what I do, none of your business but I'll answer,
For decades I've wrapped my head around complex, technical, often novel concepts, and reduce them to their essential elements for decision makers who are short on time and long on money.
With increasing profitability, I've had to do fewer of these over time, so to avoid tunnel vision, and stay fresh, I'll take a break and pursue other topics, like this one, out of pure intellectual curiosity.
A link to a single study may represent all you know, but it certainly doesn't represent all I know on this topic or the resources at my disposal to clarify anything that's not apparent. For the sake of brevity I'm not going to go into every detail of what I know in a single post. Any left unclear is a deficiency in your knowledge, not mine.
But anyone can understand these points,
-A UGL vial lacking vacuum is filled with air.
Everyone who uses UGL peptides long enough has or will encounter a vial lacking vacuum. Almost everyone understands a vial with no vacuum is undesirable. Everything your customer described is typical of a vial lacking vacuum.
-Air is 20% oxygen.
-Methionine is easily oxidized by oxygen, and the most common post translational change that occurs to rHGH and other proteins with MET. MET oxidized rHGH is inactive and increases aggregation. There are countless studies about methods to avoid this in rHGH manufacturing, it's why antioxidants are a common rHGH excipient. and why vials are vacuum sealed. Vacuum can and does leak, pulling in atmospheric air, No process is perfect, That's why pharma often injects an inert gas, to eliminate negative pressure on the stopper and reduce the chances of this happening.
We expect a lot out of Jano for very little money. As valuable as his services are, it's not reasonable to expect him to do the same in depth analysis pharma or a professional researcher would do, for $200.
I've been told Methionine oxidation is difficult to detect for several reasons. The analysis workflow can cause this oxidation, and result in "background noise", requiring time consuming steps using expensive reagents to work around it. Perhaps this is already done, making Jano's tests even more of a bargain, or perhaps it needs a more expensive test, Measuring the resulting aggregation, another risk factor ignored by UGL, also requires additional work. We'll see if he can conduct MFI to check for particulates, Perhaps even measure immunogenicity, replicating a small experiment the FDA conducted revealing what trash some compounded GLPs are, so we can gain a sense of the potential health risks UGL peptides represent, and not rely on trust, or the "haven't lost an ass cheek" standard,
I think it's time for some progress, and we're due for "Expanded Peptide/Protein Testing", Since
@readalot was so effective at moving the needle on AAS, I'll work with him, the industry experts I consult, and
@janoshik to see if we can put together a protocol to get a closer look at the important elements of these compounds, the ones pharma routinely look at for quality control, than a simple "purity & dimer" measurement can reveal.